TYGACIL, (tigecycline), glycylcyclines

INFECTIOUS DISEASES - Focus

Opinions on drugs - Posted on Oct 12 2016

Extension of Inclusion

TYGACIL now has Marketing Authorisation in children aged 8 years and older for the treatment of complicated intra-abdominal infections and complicated skin and soft tissue infections (cSSTIs), except for diabetic foot infections.
Its potential benefit is based on its broad spectrum of activity, including Gram (+) and Gram (-) bacteria that are resistant to several antibiotics.
The Marketing Authorisation is restricted to clinical situations where no suitable antibiotic is available.
Given the characteristics of the product and current uncertainties about its clinical efficacy and safety in severe infections and/or infections caused by multidrug-resistant bacteria, the therapeutic decision must be made in consultation with an antibiotics handling expert.